제목1

회사연혁

  • 2025
    • 07 기술성평가 통과
  • 2024
    • 07 NXC736 Pluto사 기술이전(신규 적응증)
    • 06 NXC680 임상1상 IND 승인
    • 04 NXC736 국가신약개발사업단(KDDF) 임상2상 과제 선정
  • 2023
    • 10 NXC736 임상2상 IND 승인
    • 07 스케일업팁스 R&D 과제 선정
    • 01 NXC680 미국 식품의약국 희귀의약품 지정
  • 2022
    • 12 NXC736 임상 1상 완료
    • 12 Series B-ext 유상증자
    • 11 직무발명 우수기업 인증
  • 2021
    • 12 SI 유상증자
    • 08 NXC736 국내 임상1상 IND 승인
    • 06 본사 이전(경기도 성남시 분당구 판교로 228번길 17)
    • 기업부설연구소(신약탐색연구소) 인증
  • 2020
    • 07 Series B 유상증자(한국산업은행, 한국투자신탁운용, 한국투자파트너스, DSC인베스트먼트 유상증자)
    • 07 방사선 폐섬유화 치료제 임상 후보물질 도출 과제 선정(과학기술정보통신부)
    • 04 NXC736 첨단의료기술 개발 과제 선정(보건복지부)
  • 2019
    • 11 기업부설연구소(신약공정연구소) 인증
    • 07 Series A 유상증자(한국투자파트너스, DSC인베스트먼트, 슈미트 유상증자)
    • 05 기업부설연구소(신약평가연구소) 인증
    • 01 벤처기업 인증
  • 2018
    • 12 Pre A 유상증자(한국투자파트너스, DSC인베스트먼트, 슈미트 유상증자)
    • 11 판교 사무실 개소(경기도 성남시 분당구 대왕판교로 670)
    • 08 넥스트젠바이오사이언스 법인설립
  • 2025
    • July Passed the KOSDAQ Listing Technology Assessment
  • 2024
    • July Technology transfer of NXC736 to Pluto (New indication)
    • June IND approval for Phase 1 clinical trial of NXC680
    • April Government funding for NXC736 Phase 2 clinical trial by KDDF
  • 2023
    • October IND approval for Phase 2 clinical trial of NXC736
    • July Government funding for Scale-up TIPS R&D program
    • January NXC680 designated as an orphan drug by the U.S. FDA
  • 2022
    • December Completion of Phase 1 clinical trial for NXC736
    • December Series B-ext funding
    • November Certification as an Excellent Company for Employee Inventions
  • 2021
    • December Strategic investment
    • August IND approval for Phase 1 clinical trial of NXC736 in Korea
    • June Office relocation Research Center certification(New Drug Discovery Center)
  • 2020
    • July Series B funding
      Government funding for RIPF treatment R&D by Ministry of Science and ICT
    • April Government funding for advanced medical technology R&D by Ministry of Health and Welfare
  • 2019
    • November Research Center certification(New Drug Process Development Center)
    • July Series A funding
    • May Research Center certification(New Drug Evaluation Center)
    • January Certificaton of Venture Enterprise
  • 2018
    • December Pre-A funding
    • November Opened Pangyo Office
    • August Founded